arrow_back Back Filing freshness 10-K FY 2026 SEC EDGAR

AYTU BIOPHARMA, INC

AYTU
$1.81 ▼ -0.06 (-2.94%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
22 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
25
Health
Poor
Bearish
auto_awesome

Analytical Summary

AYTU BIOPHARMA, INC faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $22.3M
Dividend Yield —
Revenue Growth -13.3% ↗
Op. Margin -14.4% ↘
ROIC -18.8% ↗
FCF / Share $0.26 ↗
Trailing P/E —
Price / Book 0.6x
FCF Yield 14.6%
Debt / Equity 0.26
info Valuation on last close. End-of-day price, Nov 5, 2026.

22-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$57.57M
↓ -13.3% —
Net Income Profit after all expenses
$-14.25M
↓ -5.1% —
Operating Margin Operating profit as % of sales
-14.4%
↓ -22.5% 8th
FCF / Share Free cash flow per share
$0.26
↑ +176.6% —
Long-Term Debt Long-term obligations
$9.10M
↓ -16.5% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
19
Returns ↑
18
Financial Health ↑
48
Cash Quality
16

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 22 years · 86 quarters